Treatment in childhood central nervous system demyelinating disorders.

Authors:
Bahadir Konuskan
Bahadir Konuskan
Erciyes University
Turkey
Banu Anlar
Banu Anlar
Hacettepe University
Turkey

Dev Med Child Neurol 2019 Apr 16. Epub 2019 Apr 16.

Department of Pediatric Neurology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

The last two decades witnessed significant advances in the treatment of acquired demyelinating disorders: thirteen new agents have been approved for the treatment of multiple sclerosis in adults by the European Medicines Agency and US Food and Drug Administration in the last twenty years. Although the long-term efficacy and safety profiles of some new drugs are still being assessed in paediatric MS, clinicians may have to use them in the management of paediatric onset MS resistant to first-line medications, based on results obtained in adult-onset disease. This review summarizes the current approach to treatment in children with demyelinating syndromes. WHAT THIS PAPER ADDS: Serological markers affect management in paediatric demyelinating diseases. Antibodies against aquaporin-4 and myelin oligodendrocyte glycoprotein should be tested in children with acute demyelinating disease. New therapeutic agents currently in trial for pediatric disease should be used with close follow-up.

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/dmcn.14228
Publisher Site
http://dx.doi.org/10.1111/dmcn.14228DOI Listing
April 2019
6 Reads

Article Mentions


Provided by Crossref Event Data
twitter
Twitter:
May 8, 2019, 5:21 am EST
twitter
Twitter:
May 8, 2019, 3:35 am EST
twitter
Twitter:
April 18, 2019, 4:19 am EST
twitter
Twitter:
April 18, 2019, 1:50 am EST

Publication Analysis

Top Keywords

demyelinating disorders
8
management paediatric
8
demyelinating
5
review summarizes
4
disease review
4
based adult-onset
4
adult-onset disease
4
summarizes current
4
demyelinating syndromes
4
syndromes paper
4
children demyelinating
4
treatment children
4
current approach
4
approach treatment
4
medications based
4
resistant first-line
4
drugs assessed
4
profiles drugs
4
safety profiles
4
efficacy safety
4

Altmetric Statistics

References

(Supplied by CrossRef)
Treatment with disease‐modifying drugs for people with a first clinical attack suggestive of multiple sclerosis
Filippini G et al.
Cochrane Database Syst Rev 2017

Similar Publications